ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY)

Historical Holders from Q1 2014 to Q1 2025

Symbol
ALNY on Nasdaq
CUSIP
02043Q107
Type / Class
Equity / Common Stock
Shares outstanding
130M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
128M
Holdings value
$30B
% of all portfolios
0.009%
Grand Portfolio weight change
+0.001%
Number of holders
586
Number of buys
293
Number of sells
-232
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.03% $3.53B 13.1M The Vanguard Group Mar 31, 2025
Capital Research Global Investors 5.4% $1.88B 6.97M Capital Research Global Investors Dec 31, 2024

Institutional Holders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 563K $152M +$54.4M $270.02 74
2024 Q4 128M $30B +$342M $235.31 586
2024 Q3 121M $33.4B +$488M $275.03 559
2024 Q2 120M $29.2B +$1.98B $243.00 517
2024 Q1 112M $16.8B -$859M $149.45 492
2023 Q4 115M $22.1B +$69.3M $191.41 480
2023 Q3 115M $20.4B -$246M $177.10 436
2023 Q2 117M $22.2B -$422M $189.94 457
2023 Q1 119M $23.8B +$26.4M $200.32 459
2022 Q4 118M $28.1B -$3.1B $237.65 467
2022 Q3 133M $26.6B +$3.4B $200.16 463
2022 Q2 113M $16.5B -$76.9M $145.85 397
2022 Q1 113M $18.5B +$219M $163.29 411
2021 Q4 111M $18.9B +$65M $169.58 411
2021 Q3 111M $21B -$165M $188.81 390
2021 Q2 112M $19B +$508M $169.52 389
2021 Q1 109M $15.3B +$197M $141.19 377
2020 Q4 107M $13.9B -$101M $129.97 342
2020 Q3 108M $15.8B -$457M $145.60 341
2020 Q2 111M $16.5B +$493M $148.11 358
2020 Q1 108M $11.8B +$282M $108.85 311
2019 Q4 105M $12.1B -$227M $115.17 301
2019 Q3 107M $8.59B +$172M $80.42 269
2019 Q2 106M $7.68B +$882M $72.56 278
2019 Q1 94.7M $8.85B +$410M $93.45 272
2018 Q4 91.8M $6.69B +$108M $72.91 269
2018 Q3 90.5M $7.92B -$106M $87.52 293
2018 Q2 91.5M $9.01B +$41.3M $98.49 300
2018 Q1 91.1M $10.9B -$71.7M $119.10 282
2017 Q4 91.7M $11.7B +$606M $127.05 273
2017 Q3 87.4M $10.3B +$78.6M $117.49 225
2017 Q2 87M $6.93B +$483M $79.76 214
2017 Q1 82.3M $4.22B +$358M $51.25 187
2016 Q4 79.5M $2.98B -$14.5M $37.44 198
2016 Q3 77.4M $5.25B +$230M $67.78 248
2016 Q2 74M $4.11B +$155M $55.49 238
2016 Q1 70.2M $4.41B +$303M $62.77 243
2015 Q4 65.9M $6.21B +$91.3M $94.14 255
2015 Q3 63.4M $5.1B -$70.7M $80.36 251
2015 Q2 63M $7.55B +$116M $119.87 271
2015 Q1 64.4M $6.73B +$671M $104.42 233
2014 Q4 58M $5.62B -$127M $97.00 213
2014 Q3 59M $4.61B +$102M $78.10 184
2014 Q2 57.8M $3.65B +$130M $63.17 193
2014 Q1 55.7M $3.74B +$17.9M $67.14 193